Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07596901 · ClinicalTrials.gov registry record · Phase 1
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
A Phase 1 study, sponsored by Aurinia Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT07596901: Recruiting Phase 1 study, sponsored by Aurinia Pharmaceuticals.
NCT07596901 is a Phase 1 study that is actively recruiting participants, run by Aurinia Pharmaceuticals. The registered enrollment target is 81 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07596901, a Phase 1 study, is actively recruiting participants, sponsored by Aurinia Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
Interventions
- OTHER Placebo
- DRUG Aritinercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2026-04-22 |
| Est. Completion | 2029-03-02 |
| Phase | Phase 1 |
What NCT07596901 shows while recruiting
NCT07596901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07596901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07596901 about?
NCT07596901 is a clinical study titled "Study of Aritinercept in Patients With Generalized Myasthenia Gravis". This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
What is the current status of trial NCT07596901?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2026-04-22. Estimated completion is 2029-03-02.
What interventions are being tested in trial NCT07596901?
The interventions under investigation include: Placebo (OTHER), Aritinercept (DRUG).
Who is sponsoring clinical trial NCT07596901?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07596901's enrollment target sits among peer trials
81 671st of 2000 higher than 1,329 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI